Neovasc Inc. (NVCN)
Market Cap | 82.45M |
Revenue (ttm) | 3.11M |
Net Income (ttm) | -33.52M |
Shares Out | 2.76M |
EPS (ttm) | -12.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 46,864 |
Open | 29.41 |
Previous Close | 29.42 |
Day's Range | 29.40 - 29.89 |
52-Week Range | 4.59 - 29.88 |
Beta | 2.01 |
Analysts | Buy |
Price Target | n/a |
Earnings Date | May 10, 2023 |
About NVCN
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. [Read more]
Financial Performance
In 2021, Neovasc's revenue was $2.55 million, an increase of 30.14% compared to the previous year's $1.96 million. Losses were -$24.89 million, -13.26% less than in 2020.
Financial StatementsNews

Neovasc Shareholders Approve Acquisition by Shockwave Medical
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the ...

Neovasc Announces German Reimbursement Renewal
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 1, 2023) - Neovasc, Inc. (NASDAQ : NVCN) (TSX : NVCN) ("Neovasc" or "the Company") today announced the German Institu...

Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...

Shockwave Medical to Acquire Neovasc
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for t...

Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable
Neovasc (NVCN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Neovasc (NVCN) is Your Friend, Here's Why
Neovasc (NVCN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our ...

3 Medical Instruments Stocks on Recovery Path After Dismal 2022
Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

Neovasc Announces Progress on COSIRA-II Clinical Trial
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COS...

Neovasc Comments on European Heart Journal Publication
VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case Reports...

Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
Neovasc (NVCN) delivered earnings and revenue surprises of -6.38% and 7.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for...

Neovasc Reducer Obtains U.S. Outpatient Reimbursement
VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced that the Centers for Medicare and Me...

Neovasc to Report Third Quarter Financial Results on November 10, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, ...

Neovasc Provides Corporate Update Following Clinical Data Release
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease

Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be pa...

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
VANCOUVER and MINNEAPOLIS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid ...

Neovasc Announces Key Events at TCT 2022
VANCOUVER and MINNEAPOLIS, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced its participation and presence at the Tra...

Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team ...

Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for t...

Neovasc to Report Second Quarter Financial Results on August 11, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on...

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administr...

Neovasc Announces Direct Sales Operations in United Kingdom
Expansion Driven by NICE Guidelines and Enhanced Reimbursement for the Neovasc Reducer™

Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team wil...

Neovasc to Participate in H.C. Wainwright Global Investment Conference
VANCOUVER and MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be par...

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
VANCOUVER and MINNEAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification f...